title: Protease inhibitors stimulate hematopoiesis and decrease apoptosis and ICE expression in CD34(+) cells.
abstract: Highly active retroviral therapy has been associated with a decline in the frequency of cytopenia in patients with human immunodeficiency virus (HIV) infection. This may result from lower hematologic toxicity of newer antiviral drugs and their increased efficacy against HIV-1. Protease inhibitors, in addition to their effects on HIV replication, appear to affect various cellular functions. Recently, it was reported that ritonavir inhibited caspase-1 expression in normal CD4(+) cells. It was hypothesized that protease inhibitors may improve hematopoietic function owing to their direct effects on the bone marrow progenitor cells. When ritonavir was added to methylcellulose cultures of bone marrow cells from HIV-infected patients and normal controls, colony formation increased 2.4-fold (n = 5) in control cultures and 4-fold (n = 5) in cultures of cells from HIV-infected patients. In the presence of ritonavir, cultures of CD34(+) cells showed markedly decreased apoptosis in comparison with untreated cultures (45% decrease in apoptotic cell number; n = 6). A synthetic inhibitor of caspase 1 (Ac-Tyr-Val-Ala-Asp-aldehyde [single-letter amino acid codes]), which inhibits activation of several caspases including CPP32 and interleukin 1beta-converting enzyme (ICE or caspase 1), also decreased the rate of apoptosis and enhanced colony formation by progenitor cells derived from HIV-infected patients (3-fold; n = 5). In ritonavir-treated samples derived from HIV-infected individuals, the number of cells expressing ICE also decreased. In conclusion, HIV protease inhibitors may, by blocking the caspase-dependent apoptotic pathway, overcome inhibition of hematopoiesis seen in patients with HIV infection, an effect unrelated to their antiviral activity. (Blood. 2000;96:2735-2739)
authors.affiliation: National Heart, Lung and Blood Institute, National Institutes of Health, Bethesda, MD 20892-2490, USA.
authors.forename: E M
authors.initials: EM
authors.lastname: Sloand
authors.forename: J
authors.initials: J
authors.lastname: Maciejewski
authors.forename: P
authors.initials: P
authors.lastname: Kumar
authors.forename: S
authors.initials: S
authors.lastname: Kim
authors.forename: A
authors.initials: A
authors.lastname: Chaudhuri
authors.forename: N
authors.initials: N
authors.lastname: Young
mesh_terms: D023241:Antiretroviral Therapy, Highly Active; D017209:Apoptosis / Q000187:drug effects*; D020170:Caspase 1 / Q000096:biosynthesis*; D020169:Caspases / Q000502:physiology; D002478:Cells, Cultured; D003114:Colony-Forming Units Assay; D015853:Cysteine Proteinase Inhibitors / Q000494:pharmacology; D004790:Enzyme Induction / Q000187:drug effects; D015658:HIV Infections / Q000188:drug therapy / Q000201:enzymology / Q000473:pathology*; D017320:HIV Protease Inhibitors / Q000494:pharmacology*; D006410:Hematopoiesis / Q000187:drug effects*; D006412:Hematopoietic Stem Cells / Q000166:cytology / Q000187:drug effects* / Q000201:enzymology; D009842:Oligopeptides / Q000494:pharmacology; D019438:Ritonavir / Q000494:pharmacology*
chemical_list: D015853:Cysteine Proteinase Inhibitors; D017320:HIV Protease Inhibitors; D009842:Oligopeptides; C096429:L 709049; D020169:Caspases; D020170:Caspase 1; D019438:Ritonavir